Alpha 2.0
Login Register
» Articles » PMID: 24556039

Third-line Dovitinib in Metastatic Renal Cell Carcinoma

Overview
Journal Lancet Oncol
Specialty Oncology
Date 2014 Feb 22
PMID 24556039
Citations 5
Authors
Manuela Schmidinger
Affiliations
Soon will be listed here.
Citing Articles

Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer.

Peng M, Deng J, Li X Mol Cancer. 2024; 23(1):256.

PMID: 39543657 PMC: 11566285. DOI: 10.1186/s12943-024-02167-9.

Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.

Javed Ansari M, Bokov D, Markov A, Turki Jalil A, Shalaby M, Suksatan W Cell Commun Signal. 2022; 20(1):49.

PMID: 35392964 PMC: 8991477. DOI: 10.1186/s12964-022-00838-y.

Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer.

Zahra F, Sajib M, Mikelis C Cancers (Basel). 2021; 13(6).

PMID: 33804681 PMC: 8003808. DOI: 10.3390/cancers13061422.

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.

Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A Cancers (Basel). 2019; 11(6).

PMID: 31207938 PMC: 6627706. DOI: 10.3390/cancers11060830.

Sequence of treatment in locally advanced and metastatic renal cell carcinoma.

Fischer S, Gillessen S, Rothermundt C Transl Androl Urol. 2016; 4(3):310-25.

PMID: 26816832 PMC: 4708238. DOI: 10.3978/j.issn.2223-4683.2015.04.07.